Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company released its full year 2024 financial results that showed good cash, low debt and good cost controls. The company continues with human trials, and we are looking forward to the initial results.